27887632
2016 Nov 25
Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial. We discuss reasons and implications of these negative results and the implications for clinical practice and future research.Trial registration:ClinicalTrials.gov: NCT00692770 . Registered 5 June 2008. This study has been completed.
Antiangiogenic agents; Clinical trials; Hepatectomy; Local ablation.
